Biofrontera Inc. 8K

Biofrontera Inc. reported improved Q1 2026 revenues and margins under a new cost structure, advanced multiple Ameluz clinical programs, and regained Nasdaq bid price compliance, while remaining loss-making.

Biofrontera Inc. filed a Form 8-K to furnish its press release announcing first quarter 2026 financial results and a business update, reporting a 17% year-over-year revenue increase to $10.1 million, gross margin expansion to approximately 80% driven by a new earnout structure following the October 2025 strategic transaction with Biofrontera AG, a net loss of $4.8 million and adjusted EBITDA of $(3.6) million, along with operational milestones including FDA acceptance of its sNDA for Ameluz PDT for superficial basal cell carcinoma with a PDUFA date of September 28, 2026, positive Phase 3 data in actinic keratoses on extremities/neck/trunk, positive Phase 2b acne data, database lock of a Phase 1 PK study, and regaining compliance with Nasdaq’s minimum bid price requirement as of May 6, 2026.

Filing Facts

CIK

1858685

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-022875

Alert Tier

6